Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Potential Ad Therapeutic Equipment Supplied In Europe
32 equipment items found
by:Orion Biotechnology Canada, Ltd. based inOttawa, SWITZERLAND
Orion’s platform and science unlocks the therapeutic potential of GPCR targets across a broad range of medical needs. Our approach allows us to focus our discovery and development efforts across peptide and protein GPCR subfamilies, generating a diversified pipeline of potential first-in-class/best-in-class antagonist and agonist therapies against high-value GPCR targets in ...
Manufactured by:PeptaNova GmbH based inSandhausen, GERMANY
Phebestin is a synthetic inhibitor specifically targeting alanyl-aminopeptidase, also known as aminopeptidase N (APN). It plays a significant role in modulating the proliferation and function of human peripheral T cells. This compound, characterized by its (2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl-L-valyl-L-phenylalanine structure, is soluble in water, methanol, and DMSO, offering versatile ...
Manufactured by:SpliceBio based inBarcelona, SPAIN
SpliceBio specializes in addressing the challenges of gene therapy by leveraging engineered split inteins. Traditional adeno-associated virus (AAV) vectors are limited by size, restricting their ability to package only small genes, thus leaving many monogenic diseases without effective treatment solutions. The company has focused on the innovative application of inteins, a class of proteins that ...
Manufactured by:Bayer AG based inLeverkusen, GERMANY
Small molecules (SMOLs) have long been in the focus of modern medicine. Over the last century, their advent revolutionized healthcare and improved the lives of patients all over the world. Most of today´s SMOLs exert their function by binding to proteins, thereby modulating their ability to catalyze biochemical reactions. However, a lot of proteins are difficult targets for SMOLs, since ...
Manufactured by:ExeVir Bio BV based inGhent, BELGIUM
XVR011, our lead compound is a potent, broadly neutralising SARS-COV-2 antiviral treatment. XVR011, an enhanced version of VHH72-FC, binds to a highly conserved region on the spikes of SARS-CoV-2, which are essential for the virus to enter the cell. It offers breadth and potency against a range of Sabecoviruses and is not impacted in its binding affinity to, or neutralising capacity of ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
Accessing a new repertoire of targets. Two classes of molecule with therapeutic potential that are not currently addressed by antibody drugs are G-protein-coupled receptors and ion channels, largely because they display small epitopes not accessible to traditional antibodies and their sequence is often conserved and thus less likely to be ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Three transgenes: Producing IL-12, IL-15 and a chemokine. As part of our expanding T-SIGn platform pipeline, this candidate is progressing through its IND enabling activities in readiness for entering clinical ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Novel transgene combinations. Our research team are developing a suite of viral vectors with new and innovative transgene ...
by:Reaction Biology Corp. based inMalvern, PENNSYLVANIA (USA)
ASH1L is a large , multi-domain protein associated with actively transcribed regions of chromatin, ASH1L is the human homolog of Drosophila Ash1, a Trithorax group protein. Like its counterpart in Drosophila, ASH1L contains a SET histone methyltransferase domain and has been found to play a role in the regulation of Hox gene expression. Although the ASH1L SET domain has been shown in vitro to ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Three transgenes: Producing membrane bound CD80 and secreted MIP1α and IFNa. As part of our expanding T-SIGn platform pipeline, this candidate is progressing through its IND enabling activities in readiness for entering clinical ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Two transgenes: Producing a secreted CD40 agonist monoclonal antibody. Currently in clinical trials in the US and UK. ...
Manufactured by:Sangamo Therapeutics based inBrisbane, CALIFORNIA (USA)
Sangamo’s proprietary zinc finger (ZF) platform uniquely confers a number of advantages and has broad therapeutic potential due to its versatility, specificity and clinical utility. Zinc finger technologies are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic ...
Manufactured by:PsiOxus Therapeutics Ltd. based inAbingdon, UNITED KINGDOM
Four transgenes: Producing an anti-FAP bispecific plus cytokines/chemokines. Currently in clinical trials in the US and UK. See our clinical trials page for more information. The aim of this study is to characterise the safety, tolerability and preliminary efficacy of NG-641 in patients with metastatic or advanced epithelial ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Tulmimetostat is a second-generation EZH2 inhibitor that has been designed to achieve comprehensive target coverage through extended on-target residence time. EZH2 acts as an epigenetic writer and normally places one or more methyl groups on a histone protein, leading to the suppression of gene expression. Some cancers depend on an abnormal pattern of gene expression and re-direct EZH2 to genes ...
Manufactured by:Galapagos NV based inMechelen, BELGIUM
The SIK program is a strategic effort to develop assets inhibiting salt-inducible kinases (SIK) as a novel target class in inflammation which we discovered with our proprietary target discovery platform. These molecules inhibit the different members of the SIK family and have shown the potential to modulate anti-inflammatory cytokines and pro-inflammatory cytokines. Targeted and selective ...
by:Sibylla Biotech S.p.A. based inVerona, ITALY
In Silico: Identifying small molecules able to revolutionize drug discovery. The PPI-FIT technology allows the exploration of unique pharmacological targets represented by protein folding intermediates. This places Sibylla Biotech in the exclusive position of identifying hit/lead compounds with a mechanism of action never explored so far. In this direction, we have developed an ad-hoc virtual ...
Manufactured by:EnteroBiotix Ltd based inGlasgow, UNITED KINGDOM
The gut-liver-brain axis describes the interplay of immune, metabolic and neuroendocrine biology that is increasingly being recognised as a potential therapeutic ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells, without broad suppression of ...
Manufactured by:Exeliom Biosciences based inDijon, FRANCE
Faecalibacterium prausnitzii (F. prau), a key bacterium to treat Crohn’s Disease Meet Faecalibacterium prausnitzii (F. prau) WHAT IS F. prau? F. prau, is a dominant member of the healthy gut microbiome. It accounts for 5% to 15% of the total fecal microbiome in healthy adults, which is simply colossal. F. prau is the most extreme example of strict anaerobic bacteria. In other words, F. prau ...
Manufactured by:GENFIT based inLoos, FRANCE
Primary Biliary Cholangitis (PBC) is a chronic disease in which bile ducts in the liver are gradually destroyed.1 The damage to bile ducts can inhibit the liver’s ability to rid the body of toxins, and can lead to cirrhosis. Targeting PPAR receptors may result in a reduction of bile acid synthesis, improved detoxification of bile in the bile duct and anti-inflammatory activity. The use of ...